Quanterix posted Q2 revenue of $32.9 million, up 34% year over year, as GAAP net loss widened to $48.93 million.
GAAP gross margin slipped 2.4 percentage points to 38.5%, while non-GAAP adjusted EBITDA loss narrowed to $10 million from $13.7 million.
Cash, cash equivalents, marketable securities, and restricted cash totaled $96.9 million; it recorded a $26.9 million GAAP goodwill impairment tied to Akoya.
Outlook cut: 2026 revenue seen at $142 million-$148 million; cash-flow breakeven now expected in 2027 with about $80 million year-end cash.
Management cited execution challenges and market softness; Anthem Blue Cross and Blue Shield began covering Lucent AD Complete qualifying blood-based biomarker testing from July 1.
QTRX•
